Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2015', provides an overview of the Valeant Pharmaceuticals International, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Valeant Pharmaceuticals International, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Valeant Pharmaceuticals International, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Valeant Pharmaceuticals International, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Valeant Pharmaceuticals International, Inc.'s pipeline products

Reasons to buy

- Evaluate Valeant Pharmaceuticals International, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Valeant Pharmaceuticals International, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Valeant Pharmaceuticals International, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Valeant Pharmaceuticals International, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valeant Pharmaceuticals International, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Valeant Pharmaceuticals International, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Valeant Pharmaceuticals International, Inc. Snapshot 5
Valeant Pharmaceuticals International, Inc. Overview 5
Key Information 5
Key Facts 5
Valeant Pharmaceuticals International, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Valeant Pharmaceuticals International, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance 12
Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Valeant Pharmaceuticals International, Inc. - Drug Profiles 15
IDP-118 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
loteprednol etabonate next generation 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
methylnaltrexone bromide 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CB-0301 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ezogabine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PDI-192 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PDI-320 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IDP-120 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Valeant Pharmaceuticals International, Inc. - Pipeline Analysis 28
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target 28
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration 29
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type 30
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action 31
Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates 32
Valeant Pharmaceuticals International, Inc. - Dormant Projects 36
Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
(bupropion hydrochloride + selective serotonin reuptake inhibitor) 37
CVTE-002 37
ezogabine 38
IDP-107 38
IDP-115 38
MC-5 38
methylnaltrexone bromide 38
RUS-350 38
tiazofurin 38
UK-279276 38
Valeant Pharmaceuticals International, Inc. - Company Statement 39
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Valeant Pharmaceuticals International, Inc., Key Information 5
Valeant Pharmaceuticals International, Inc., Key Facts 5
Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2015 7
Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2015 8
Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2015 9
Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2015 10
Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
Valeant Pharmaceuticals International, Inc. - Phase III, 2015 12
Valeant Pharmaceuticals International, Inc. - Phase II, 2015 13
Valeant Pharmaceuticals International, Inc. - Phase I, 2015 14
Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2015 28
Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2015 29
Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2015 30
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2015 31
Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2015 32
Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2015 36
Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2015 37
Valeant Pharmaceuticals International, Inc., Other Locations 41
Valeant Pharmaceuticals International, Inc., Subsidiaries 42